Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isolated Foam Sclerotherapy vs CLaF for Reticular Veins and Telangiectasias
NCT07793630Phase 4Recruiting
- Sponsor
- Universidade de São Paulo
- Start
- Sep 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of 10XB101 in telangiectasia and chronic venous disease (CVD) (2 arms), sponsored by Universidade de São Paulo. Primary endpoint: Percent Change in Residual Vascular Area at 180 days. Started Sep 2026; status: recruiting.
02
Drugs
10XB101
03
Conditions
telangiectasiachronic venous disease (CVD)
Beyond the preview
Go deeper on NCT07793630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07793630.